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Objectives This study was designed to establish the incidence, impact, and predictors of post-transcatheter aortic valve re-
placement (TAVR) aortic regurgitation (AR).
Background AR is an important limitation of TAVR with ill-defined predictors and unclear long-term impact on outcomes.
Methods Studies published between 2002 and 2012 with regard to TAVR were identified using an electronic search and
reviewed using the random-effects model of DerSimonian and Laird. From 3,871 initial citations, 45 studies re-
porting on 12,926 patients (CoreValve [Medtronic CV Luxembourg S.a.r.l., Tolochenaz, Switzerland] n  5,261
and Edwards valve [Edwards Lifesciences, Santa Ana, California] n  7,279) were included in the analysis of
incidence and outcomes of post-TAVR AR.
Results The pooled estimate for moderate or severe AR post-TAVR was 11.7% (95% confidence interval [CI]: 9.6 to
14.1). Moderate or severe AR was more common with use of the CoreValve (16.0% vs. 9.1%, p  0.005). The
presence of moderate or severe AR post-TAVR increased mortality at 30 days (odds ratio: 2.95; 95% CI: 1.73 to
5.02) and 1 year (hazard ratio: 2.27; 95% CI: 1.84 to 2.81). Mild AR was also associated with an increased
hazard ratio for mortality, 1.829 (95% CI: 1.005 to 3.329) that was overturned by sensitivity analysis. Twenty-
five studies reported on predictors of post-TAVR AR. Implantation depth, valve undersizing, and Agatston calcium
score (r  0.47, p  0.001) were identified as important predictors.
Conclusions Moderate or severe aortic regurgitation is common after TAVR and an adverse prognostic indicator of short- and
long-term survival. Incidence of moderate or severe AR is higher with use of the CoreValve. Mild AR may be as-
sociated with increased long-term mortality. Therefore, every effort should be made to minimize AR by a com-
prehensive pre-procedural planning and meticulous procedural execution. (J Am Coll Cardiol 2013;61:
1585–95) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.047Transcatheter aortic valve replacement (TAVR) is a rapidly
evolving technology that has been shown to be a durable
alternative to surgical aortic valve replacement in patients
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2013, accepted January 15, 2013.with severe, symptomatic aortic stenosis considered a high
or prohibitive operative risk. In the randomized PART-
NER (Placement of AoRTic TraNscathetER Valve Trial)
trial (1,2), TAVR exceeded expectations by decreasing
mortality and improving quality of life in patients at
prohibitive risk of surgical aortic valve replacement. Fueled
by these results that had earlier been replicated in large
prospective registries (3–5), there has been an exponential
increase in TAVR procedures across the globe with specu-
lations of its extension to a low-risk population. However,
despite the progress made, there remain several potential
TAVR limitations that need to be minimized before imple-
menting this approach in low-risk patients.
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Aortic Regurgitation After TAVR April 16, 2013:1585–95Aortic regurgitation (AR) re-
mains a frequent complication
of TAVR, with yet unexplained
determinants and clinical conse-
quences. Depending on the method
of assessment (angiography vs.
echocardiography, quantitative vs.
semiquantitative), the reported prev-
alence of AR after TAVR varies
from 40% to 67% (6–8) for trivial to
mild leaks and from 7% to 20%
(3,6–8) for moderate to severe leaks.
What constitutes clinically signifi-
cant valve regurgitation after TAVR
is not fully established and is cur-
rently a matter of utmost impor-
tance. Earlier reports suggested that
ild AR is benign and well tolerated (9). However, a recent
tudy (10) revealed that even mild paravalvular leak is an
dverse prognostic indicator. The limited yet concerning
vidence against AR emphasizes the need for further inves-
igation and to identify variables that can be modified to
inimize paravalvular leak.
The objective of our meta-analysis was to identify all
urrently published literature to establish the incidence of
ost-procedural AR, its impact on outcomes after TAVR,
nd its predictors.
ethods
tudy selection. We conducted a systematic review of the
ublished literature on post-TAVR AR following the
UOROM (Quality of Reporting of Meta-Analysis) (11)
and MOOSE (Meta-Analysis of Observational Studies in
Epidemiology) (12) guidelines. We performed a computer-
ized search to identify all relevant studies published from
January 1, 2002, to May 5, 2012, in the PubMed database.
We chose 2002 because that was the year that Dr. Cribier in
Rouen, France, performed the first-in-human TAVR (13).
The following search terms were used: TAVI, percutaneous
valves, transcutaneous aortic valve, and transcatheter aortic
valve. Citations were screened at the title and abstract level
nd retrieved as a full report if they reported on outcomes
fter TAVR. The search term regurgitation was then used in
each retrieved paper to single out papers reporting data on
post-procedural AR. Limiting the search parameters to the
English language was applied subsequently. The full texts
and bibliography of all potential articles also were reviewed
in detail (G.A.) to seek additional relevant studies.
Inclusion criteria. Studies were included if the following
criteria applied: 1) reported data on post-TAVR AR sever-
ity or predictors of AR or mortality outcomes based on AR
severity; 2) reported to have enrolled consecutive patients; 3)
performed a minimum of 30 successful TAVR procedures;
and 4) enrollment for TAVR was based on existing and
Abbreviations
and Acronyms
AR  aortic regurgitation
CI  confidence interval
HR  hazard ratio
OR  odds ratio
TAVR  transcatheter
aortic valve replacement
TEE  transesophageal
echocardiography
3D  3-dimensional
TTE  transthoracic
echocardiography
VARC  Valve Academic
Research Consortiumaccepted guidelines. When 2 similar studies were reported efrom the same institution or author, the most recent
publication or the publication with the most information on
post-TAVR AR was included in the analysis.
Exclusion criteria. Studies were excluded if any of the
following criteria applied: 1) duplicate publication, overlap
of patients, subgroup studies of a main study; 2) lack of data
on post-TAVR AR severity; 3) outcome of interests was not
clearly reported or was impossible to extract or calculate
from the published results; 4) they were studies on valve-
in-valve procedure; and 5) a valve other than the CoreValve
(Medtronic CV Luxembourg S.a.r.l., Tolochenaz, Switzer-
land) or Edwards valve (Edwards Lifesciences, Santa Ana,
California) was used.
Definitions. POST-PROCEDURAL AR. For the purpose of
the current analysis, post-procedural AR included AR
reported immediately after the procedure, AR at discharge,
or AR at 30-day follow-up. AR: none  0/4, mild  1/4,
moderate  2/4, severe  3 to 4/4.
COREVALVE OR EDWARDS VALVE. A study that performed
80% or more of the TAVR procedures with either valve was
subcategorized to the respective group. Studies with less
than 80% predominance of either valve were excluded from
the analysis of CoreValve versus Edwards valve. Individual
data where provided were incorporated in the analysis
irrespective of valve predominance.
Data extraction. Relevant information was collected and
included but was not limited to first author, year and journal
of publication, study design, inclusion exclusion criteria,
definition of primary and secondary endpoints, number of
subjects included, subjects undergoing successful TAVR,
type of device and approach used, study population demo-
graphics, echocardiographic parameters post-TAVR,
follow-up period, and primary and secondary outcomes.
DATA EXTRACTION: MILD AR. To date, only 2 studies
10,14) have reported data on the long-term outcome of
ild AR post-TAVR. Therefore, to investigate the out-
ome of mild AR, we corresponded with trial authors and
nvited participation in our study. We contacted study
uthors who reported the outcome of AR post-TAVR.
uthors from 4 groups responded. The responding authors
nalyzed their data and provided us with the hazard ratio
HR) of 1-year mortality for mild AR compared with no
R post-TAVR (4,14–16).
tudy endpoints. The primary endpoints evaluated were:
) overall incidences of moderate or severe AR post-TAVR;
) effect of post-TAVR AR on 30-day and long-term
ortality; and 3) predictors of AR. Secondary endpoints
f interest were AR incidence stratified by valve used
CoreValve vs. Edwards valve) and by individual grades
none mild, moderate, or severe).
tatistical analysis. DerSimonian and Laird’s random-
ffects model was used to pool the estimates of post-TAVR
R from individual studies and subgroups. A random-ffects model also was used to obtain a single pooled
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April 16, 2013:1585–95 Aortic Regurgitation After TAVRestimate of the HRs, odds ratios (ORs), and correlation
from the individual studies. The effect across subgroups was
compared using a Q test based on analysis of variance. The
odds function, where appropriate, was converted to a
correlation. The HRs were estimated from the survival
curves when not reported by the method proposed by
Parmar et al. (17). Statistical significance was set at p 0.05
(2-tailed). Heterogeneity, which was anticipated to be
significant, was assessed by a Q-statistic and I2 test. Signif-
icant heterogeneity was considered present for p values
0.10 or an I250%. Sensitivity analysis was performed by
deleting one study at a time and switching from a random-
effects to a fixed-effects analysis. Data analysis was per-
formed using Comprehensive Meta Analysis Software Ver-
sion 2 (18).
Results
Through a search by keywords, 3,871 reports were identified
and reviewed at title and abstract level (Fig. 1). Initial
evaluation identified 1,180 publications that were further
evaluated using the search term regurgitation. This narrowed
the selection to 158 potential publications. Manual search of
the bibliographies further identified 8 relevant publications.
When the inclusion and exclusion criteria were applied, 45
publications remained for assessment (3–5,10,14–16) (On-
line Refs. 1–38) of incidence and outcomes of post-TAVR
AR and 25 publications remained for predictors of AR (15)
(Online References 9,12,13,39–59). The 45 included pub-
Figure 1 Flow Chart Showing Selection of Studies
*Different valve, n  2; nonconsecutive patients, n  8; 30 patients, n  19; i
AR  aortic regurgitation; TAVI  transcatheter aortic valve implantation; TAVR lications had 2 randomized comparisons (10) (Online Ref.
25) and 43 observational studies (3–5,14–16) (Online Refs.
1–4,26–38).
All the studies included in the analysis were published
between 2008 and 2012 (Table 1). Analysis was performed
on 12,926 patients, the transfemoral/subclavian approach
was used in 8,408 patients (65.1%), and the transapical/
aortic approach was used in 3,995 patients (30.9%). The
approach used was unavailable in 523 patients (4%) (14,16).
The self-expanding CoreValve was implanted in 5,261
patients (40.7%), and the balloon-expandable Edwards
valve was implanted in 7,279 patients (56.3%). Of the 45
publications, 42 studies (3–5,10,14–16) (Online Refs.
–32,36–38) provided enough details on the primary end-
oint of moderate or severe AR post-TAVR. The remain-
ng 3 studies (Online Refs. 33–35) did not provide details
n moderate AR but reported the incidence of severe AR
ost-TAVR.
The pooled estimate for overall incidence of moderate or
evere AR was 11.7% (95% confidence interval [CI]: 9.6 to
4.1, I2  91.22, Q  467.37) (Fig. 2). The Valve
cademic Research Consortium (VARC) definitions were
sed in 12 papers (14,15) (Online Refs. 2,7,15,19,
1,22,28,34,35,37). Pooled estimate of moderate or severe
R from papers that reported on the basis of VARC was
3.9% (95% CI: 9.8 to 19.3, I2  92.63, Q  122.09) and
without VARC definitions was 10.8% (95% CI: 8.5 to 13.7,
I2  90.4, Q  322.71). Papers that did not report on the
asis of VARC failed to report the grading method or used
he Sellers angiographic criteria or the American Society of
ient data, n  23; duplicates/overlaps/same center studies, n  63.
atheter aortic valve replacement.nsuffic
transc
i
Q
E
I
C
1588 Athappan et al. JACC Vol. 61, No. 15, 2013
Aortic Regurgitation After TAVR April 16, 2013:1585–95Echocardiography/European Society of Endocrinology
guidelines for transthoracic echocardiography (TTE). The
incidence of AR reported by these reports did not differ
significantly from reports using the VARC guidelines (Q 
1.35, p  0.25).
The incidence of moderate or severe AR after CoreValve
mplantation was 16.0% (95% CI: 13.4 to 19.0, I2  74.81,
Selected Studies on the Incidence of AR Post-TAVRTable 1 Selected Studies on the Incidence of AR Post-TAVR
First Author (Ref. #) Center
Rodés-Cabau et al. (3) Canada (multicenter) Mar
Tamburino et al. (4) Italy (multicenter) Janu
Moat et al. (5) UK (multicenter) Nov
Kodali et al. (10) USA Mar
Lemos et al. (14) Sao Paulo, Brazil May
Sinning et al. (15) Bonn, Germany Mar
Fraccaro et al. (16) Italy (multicenter) Apri
Bagur et al. (Online Ref. 1) Quebec, Canada Feb
Gurvitch et al. (Online Ref. 2) Vancouver, Canada May
Lefevre et al. (Online Ref. 3) International multicenter Janu
Eltchaninoff et al. (Online Ref. 4) France (multicenter) Sep
Attias et al. (Online Ref. 5) France (multicenter) Apri
Tchetche et al. (Online Ref. 6) Toulouse, France Janu
Hayashida et al. (Online Ref. 7) Massy, France Feb
Abdel-Wahab et al. (Online Ref. 8) Germany (multicenter) Mar
Unbehaun et al. (Online Ref. 9) Berlin, Germany Janu
Conradi et al. (Online Ref. 10) Hamburg, Germany Janu
Lange et al. (Online Ref. 11) Munich, Germany Janu
Leber et al. (Online Ref. 12) Munich, Germany Dec
Chorianopoulos et al. (Online Ref. 13) Heidelberg, Germany Apri
Grube et al. (Online Ref. 14) Siegburg, Germany Dec
Grube et al. (Online Ref. 15) International multicenter July
Walther et al. (Online Ref. 16) Germany (multicenter) Feb
Stohr et al. (Online Ref. 17) Aachen, Germany Dec
Sherif et al. (Online Ref. 18) Germany (multicenter) Nov
Puls et al. (Online Ref. 19) Göttingen, Germany Feb
Gotzmann et al. (Online Ref. 20) Bochum, Germany Aug
Amabile et al. (Online Ref. 21) France and USA Mar
Buchanan et al. (Online Ref. 22) Milan, Italy Sep
D’Onofrio et al. (Online Ref. 23) Italy (multicenter) Aug
Ewe et al. (Online Ref. 24) International multicenter Octo
Makkar et al. (Online Ref. 25) USA Mar
Munoz-Garcia et al. (Online Ref. 26) Ma´laga, Spain Apr
Goncalves et al. (Online Ref. 27) Madrid, Spain May
Wenaweser et al. (Online Ref. 28) Bern, Switzerland Nov
Dworakowski et al. (Online Ref. 29) London, UK Aug
Jabbour et al. (Online Ref. 30) London, UK Nov
Piazza et al. (Online Ref. 31) International multicenter Aug
Buellesfeld et al. (Online Ref. 32) International multicenter Apr
Thomas et al. (Online Ref. 33) International multicenter Apr
van der Boon et al. (Online Ref. 34) Rotterdam, Netherlands Janu
Stahli et al. (Online Ref. 36) Bern, Switzerland Aug
Kodali et al. (Online Ref. 36) USA Mar
Gilard et al. (Online Ref. 37) France May
Wendler et al. (Online Ref. 38) International multicenter Apr
AA  transaortic; AX  transaxillary; ES  Edwards valve; IL  transiliac; MC  Medtronic CoreV 59.56). The incidence of moderate or severe AR after 4dwards valve implantation was 9.1% (95% CI: 6.2 to 13.1,
2  93.63, Q  313.72). Moderate or severe AR was seen
more often with the use of the self-expanding CoreValve
(Q  7.71, p  0.005) (Fig. 3).
The overall pooled estimate was 1.6% (95% CI: 1.1 to
2.4, I2  80.48, Q  194.63) for severe AR, 10.5% (95%
I: 8.4 to 13.1, I2  89.53, Q  324.84) for moderate AR,
r n Approach Valve Follow-Up
0 339 TF/TA ES 1 yr
11 663 TF/SC MC 1 yr
2011 870 TF/TA ES/MC 2 yrs
2 348 TF/TA ES 2 yrs
79 MC 1 yr
2 146 TF/SC MC 1 yr
384 TF/SC/TA ES/MC 1 yr
011 100 TA ES 6 months
310 TF/TA ES 30 days
11 130 TF/TA ES 1 yr
r 2010 244 TF/TA ES/MC 30 days
83 TF ES/MC 1 yr
10 45 TF ES/MC 30 days
012 260 TF/TA/SC ES/MC 1 yr
1 690 TF/TA/SC/AA ES/MC 30 days
12 358 TA ES 2 yrs
12 82 TF/TA ES 30 days
12 415 TF/TA/SC/AA ES/MC 6 months
2011 68 TF MC 1 yr
70 TF MC 1 yr
2008 136 TF/SC/IL MC 1 yr
60 TF MC 30 days
012 299 TA ES 3 yrs
2011 175 TF/TA MC/ES 30 days
2010 56 TF MC 30 days
012 180 TF/TA ES/MC 1 yr
11 145 TF/SC MC 6 months
2 126 TF/TA ES/MC 1 yr
r 2011 305 TF/TA/AX/AA ES/MC 30 days
11 504 TA ES 2 yrs
11 104 TF/TA ES 30 days
2 179 TF ES 2 yrs
141 TF/SC MC 6 months
74 TF/TA MC/ES 6 months
2011 257 TF/TA/SC ES/MC 2.5 yrs
10 151 TF/TA ES 30 days
2011 87 TF ES/MC —
08 646 TF MC 30 days
126 TF/SC MC 2 yrs
1,038 TF/TA ES 1 yr
12 230 TF/SC MC 30 days
11 130 TF/TA ES/MC 1 yr
1 55 TF ES 1 yr
3,195 TF/SC/TA/TC/AA ES/MC 1 yr
120 TA ES 1 yr
 number of patients; SC  subclavian; TA  transapical; TC  transcarotid; TF  transfemoral.Yea
ch 201
ary 20
ember
ch 201
2012
ch 201
l 2012
ruary 2
2011
ary 20
tembe
l 2010
ary 20
ruary 2
ch 201
ary 20
ary 20
ary 20
ember
l 2012
ember
2011
ruary 2
ember
ember
ruary 2
ust 20
ch 201
tembe
ust 20
ber 20
ch 201
il 2011
2011
ember
ust 20
ember
ust 20
il 2011
il 2010
ary 20
ust 20
ch 201
2012
il 2012
alve; N5.9% (95% CI: 40.8 to 51.0, I2  95.32, Q  705.78) for
w
1
1
p
o
m
a
e
m
t
e
t
D
A
o
a
1
1589JACC Vol. 61, No. 15, 2013 Athappan et al.
April 16, 2013:1585–95 Aortic Regurgitation After TAVRmild/trivial AR, and 35.8% (95% CI: 30.0 to 42.0, I2 
96.82, Q  1,037.78) for none.
Our search for predictors of TAVR identified several
publications on 3 major culprits (Table 2). The computed
tomography-derived mean Agatston calcium score posi-
tively correlated with the development of post-TAVR
moderate or severe AR with a pooled estimate of correlation
being r  0.47 (95% CI: 0.30 to 0.61, p  0.001, I2 
76.24, Q  12.63). The other 2 predictive factors that were
reported could not be pooled because of limited studies and
variable reporting.
The overall 1-year mortality was unfavorable in patients
with moderate or severe AR with an HR of 2.27 (95% CI:
1.84 to 2.81, p  0.001, I2  26.02, Q  10.81) (Fig. 4).
The OR of 30-day mortality was increased in patients with
moderate or severe AR post-TAVR, 2.95 (95% CI: 1.73 to
5.02, p 0.001, I2 0, Q 2.663). Mild AR post-TAVR
as associated with significant mortality, with an HR of
Figure 2 Forest Plot Showing the Individual and Pooled Event R
for Moderate or Severe AR After TAVR From the Inclu
AR  aortic regurgitation; CI  confidence interval; TAVR  transcatheter aortic va.829 (95% CI: 1.005 to 3.329, p 0.048, I2 75.28, Q c6.18) (Fig. 5). The analysis was performed on 1,620
atients across 5 individual studies.
We explored the robustness of our findings by omitting
ne study at a time or outlier studies and switching our
eta-analysis model from a random- to a fixed-effects
nalysis. There was no change in the summary effects by
ither analysis other than for mild AR. The pooled HR for
ortality with mild AR became insignificant on removal of
he studies by Lemos et al. (14), Kodali et al. (10), Sinning
t al. (15), and Fraccaro et al. (16) (Fig. 6). Nevertheless,
here was a trend toward increased mortality.
iscussion
R after TAVR. The impact of mild AR on long-term
utcomes has yielded conflicting results. In our pooled
nalysis, mild AR was associated with a 1-year hazard of
.940 (95% CI: 1.090 to 3.452). However, the conclusions
tudies
placement.ates
ded S
lve rehanged when studies were removed from the analysis set
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Aortic Regurgitation After TAVR April 16, 2013:1585–95one at a time. This discrepancy in outcomes may be related
in part to the challenges in identification and quantification
of post-TAVR AR. Post-TAVR AR is frequently paraval-
vular, created by multiple eccentric jets that are nonparallel
and irregular in shape (9,19). The eccentric jets in turn are
Figure 3 Forest Plot Showing the Individual and Pooled Event R
for Moderate or Severe AR After TAVR From the Inclu
With use of the CoreValve (A) and Edwards valve (B). Q between the 2 subgroups
and statistically significant (p  0.000), meaning that the event rate was related tfrequently entrained along the LV wall with fanning of jetsas they regurgitate. This makes the assessment of AR
severity difficult and more subjective. Acoustic shadowing
from the calcifications, reverberations, and Doppler atten-
uation from the prosthesis can further obscure significant
regurgitant jets and result in underestimation of its severity
tudies
Valve vs. Edwards valve) was 10.66
type of valve implanted. Abbreviations as in Figure 2.ates
ded S
(Core
o the(9). Various echocardiographic techniques (19,20) and
D
n
t
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April 16, 2013:1585–95 Aortic Regurgitation After TAVRSelected Studies on Predictors of AR Post-TAVRTable 2 Selected Studies on Predictors of AR Post-TAVR
Predictor First Author (Ref. #) Variable
Association With Post-TAVR Moderate or Severe
AR
Valve undersizing Detaint et al. (Online Ref. 39) Cover index Low cover index was associated with mild or greater
AR; OR: 1.22 (95% CI: 1.03–1.51, p  0.02)
Sinning et al. (15) Cover index Low cover index was associated with mild or greater
AR (p  0.001)
Samim et al. (Online Ref. 40) Cover index High cover index associated with absence of AR
Haensig et al. (Online Ref. 41) Prosthesis mismatch (annulus  prosthesis) Undersizing associated with mild or greater AR
(p  0.002)
Willson et al. (Online Ref. 42) Prosthesis mismatch (prosthesis – mean
annulus diameter) 1 mm
Undersizing associated with mild or greater AR:
OR: 9.4 (95% CI: 2.15–88.8, p  0.01)
Buzzatti et al. (Online Ref. 43) Prosthesis mismatch (prosthesis – Dmean)/Dmean Undersizing associated with mild or greater AR
(p  0.0006)
Larger annulus size Dmax (p  0.0003), Dmin (p  0.0113 ),
Dmean (p  0.001)
Schultz et al. (Online Ref. 44) Larger annulus size Dmax (p  0.05), Dmin (p  0.05), DCSA (p  0.01)
associated with mild or greater AR
Takagi et al. (Online Ref. 45) Prosthesis mismatch (annulus  prosthesis) Association with mild or greater AR (p  0.056)
Larger annulus size OR: 1.78 (95% CI: 1.25–2.55, p  0.002)
Altiok et al. (Online Ref. 46) Annulus size: 2D TEE vs. 3D TEE vs. DSCT Significant difference in measurement of AV annulus
by 2D TEE vs. DSCT (average bias  1.7 mm;
p  0.001); strong correlation between 3D TEE
and DSCT
Jilaihawi et al. (Online Ref. 47) Annulus size: CT vs. TEE CT annular assessment superior to TEE (p  0.045)
Husser et al. (Online Ref. 48) Annulus size: 2D TEE vs. 3D TEE Mean AV diameters significantly larger in 3D TEE vs.
2D TEE (23.4 2.2 mm vs. 22.1 2.6 mm;
p  0.001)
Kalavrouziotis et al. (Online Ref. 49) Annulus size 20 mm Only 2.9% incidence of mild or greater AR after
implantation of 23-mm valve
Aortic valve
calcification
Shultz et al. (Online Ref. 50) Agatston score Higher with mild or greater AR (p  0.05)
Koos et al. (Online Ref. 51) Agatston score
Morphological risk
r  0.50, p  0.001
No association identified
Delgado et al. (Online Ref. 52) Agatston score
Morphological risk
Higher with moderate or severe AR post-TAVR
(p  0.005)
Aortic valve commissure
John et al. (Online Ref. 53) Agatston score
Morphological risk
r  0.254, p  0.011
LVOT and aortic valve – DLZ
Unbehaun et al. (Online Ref. 9) Agatston score
Morphological risk
OR  1.09 (95% CI: 1.01–1.17), p  0.029
DLZ calcification OR: 4.90
Haensig et al. (Online Ref. 41) Agatston score
Morphological risk
OR  11.38 (95% CI: 2.33–55.53), p  0.001
Calcification at right and left coronary cusps
Colli et al. (Online Ref. 54) Echocardiographic calcium score
Morphological risk
OR  8.5 (95% CI: 1.2–58.9); p  0.0001
Aortic commissures and valve cusp
Ewe et al. (Online Ref. 55) Morphological risk Aortic wall calcification: AUC: 0.93 (p  0.001)
Valve commissure calcification: AUC: 0.94
Leber et al. (Online Ref. 12) Calcium mass score r  0.33, p  0.002
Wood et al. (Online Ref. 56) Agatston score No association with AR (p  0.35)
Staubach et al. (Online Ref. 57) Visual estimation of valve calcification No association with AR
Implantation
depth
Sherif et al. (Online Ref. 58) Depth from NCC Least at depth 10 mm; deep and shallow
implantation increased AR
Jilaihawi et al. (Online Ref. 59) Depth from NCC Implantation 15 mm associated with mild or
greater AR (p  0.032)
Chorianopoulos et al.
(Online Ref. 13)
Depth* OR: 1.3 (95% CI: 1.1–1.6, p  0.0098)
Sinning et al. (15) Depth from LCC Significantly higher in moderate or greater AR
(p  0.029)
Takagi et al.(Online Ref. 45) Low implantation 3 struts below annulus OR  3.67 (95% CI: 1.01–13.35, p  0.049)
Schultz et al. (Online Ref. 50) Implantation depth No association with AR
Implantation depth was determined by calculating the distance between an imaginary line joining basal attachment points of aortic valve leaflets with the line connecting the right and left lower prosthesis skits.
AR aortic regurgitation; AUC area under the curve; AV aortic valve; CI confidence interval; CT computed tomography; DLZ device landing zone; Dmaxmaximum aortic annulus diameter;
mean  mean aortic annulus diameter; Dmin  minimum aortic annulus diameter; DSCT  dual-source computed tomography; LCC  left coronary cusp; LVOT  left ventricular outflow tract; NCC 
oncoronary cusp; OR  odds ratio; r  correlation coefficient; TAVR  transcatheter aortic valve replacement; 2D TEE  2-dimensional transesophageal echocardiography; 3D TEE  3-dimensional
ransesophageal echocardiography.
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proposed to measure the severity of post-TAVR AR;
however, none of these techniques have been validated and
the grading system has not been clearly defined (difference
between mild, trivial, or trace, mild vs. moderate, moderate
vs. severe). Therefore, the assessment of post-TAVR AR
remains controversial and imprecise (21).
Sherif et al. (22) demonstrated an underestimation of the
AR severity after implantation of the Core Valve by current
echocardiography criteria compared with cardiac magnetic
resonance. The VARC (23), which was developed to
propose standardized consensus definitions to report post-
TAVR complications, failed to adequately address paraval-
vular leak in its current report. The VARC did not propose
standard terminologies or new diagnostic criteria for assess-
ment of AR, but merely elaborated on the work done by
others and summarized by Zoghbi et al. (20). The lack of
core laboratory assessment of AR severity in the included
studies and the absence of published standards for post-
TAVR AR may have affected the quality of the reported
data. This issue of imprecision is a major limitation in
comparing echocardiographic studies performed in dif-
ferent laboratories and likely contributed to the discor-
dant results on the outcome of mild AR. To develop
standard criteria to achieve uniformity and accurate
Figure 4 Forest Plot Showing the HRs of Moderate or Severe A
*Includes mild AR in the analysis of HR. HR  hazard ratio; other abbreviations aFigure 5 Forest Plot Showing the HRs of Mild AR on Overall Mortaligrading of paravalvular AR post-TAVR is therefore a
pressing necessity.
To complicate the matter further, it is possible that AR is
a surrogate for an underlying cause, such as severe valve
calcification or sicker patients. The role of other confound-
ing variables, such as pre-procedural AR, left ventricle
function, and mitral regurgitation, remains unclear at pres-
ent. However, the impact of moderate to severe AR is more
apparent with a pooled 30-day OR for mortality of 2.95
(95% CI: 1.73 to 5.02) and a long-term HR of 2.27 (95%
CI: 1.84 to 2.89).
CoreValve versus Edwards valve. Regardless of the valve
type, post-TAVR AR was a frequent complication in reported
studies. Nevertheless, implantation of the CoreValve carried a
higher risk of post-TAVR AR (16.0% vs. 9.1%, p  0.005).
Concerns have been raised over the radial strength of the
nitinol frame of the self-expanding CoreValve in highly
calcific lesions (Online Refs. 13,26,51). Incomplete device
expansion and resultant impaired apposition of the Core
Valve to the native annulus and the left ventricular outflow
tract have been implicated in these cases. Another possible
cause for AR after core valve implantation is the extreme
angulation between the left ventricular outflow tract and the
ascending aorta, which reduces the ability of the self-
expanding prosthesis to form a tight seal to close the
Overall Mortality
ure 2.R on
s in Figty
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oversizing as opposed to the Edwards valve may overcome
the underexpansion of the CoreValve in these situations.
However, balloon post-dilation has been associated with
increased stroke risk (24). Another factor that is important
for reducing AR when the CoreValve is used is the height
of implantation. Because of the noncylindrical shape of the
valve, the depth of implantation determines the effective
diameter of the valve in the annulus. Particularly in larger
annuli, the sealing of the CoreValve at the level of the
virtual ring is dependent on a high implantation to take
advantage of the diameter of the lower part of the valve.
Predictive factors and potential management strategies.
Mismatch of the valve annulus and prosthesis diameter
sizes, aortic root calcification, and suboptimal device im-
plantation were identified as the major causes for post-
TAVR AR in our search.
Valve undersizing. Undersizing of the prosthesis relative
to the annulus size is the central cause for most paravalvular
leaks after TAVR. Detaint et al. (Online Ref. 39) studied
the effect of undersizing using the cover index [100 · (pros-
thesis diameter transesophageal echocardiography [TEE]
annulus diameter)/prosthesis diameter]. A low cover index
was found to be an independent predictor of moderate or
severe AR post-TAVR. This has been replicated in 2 other
studies (15) (Online Ref. 40). Appropriate cover index for
each valve may be different and requires more studies to
clearly define this.
Therefore, precise annulus sizing by appropriate aortic
imaging pre-TAVR is fundamental to prevent AR (25).
The aortic annulus was initially sized by 2-dimensional
measurements obtained from TTE, but there are several
limitations to annulus sizing using TTE. TTE has been
shown to underestimate the annulus size from anywhere
between 1.4 mm and 1.7 mm (26) (Online Ref. 42). Similar
underestimation may occur with TEE (1.2 mm) (26).
Jilaihawi et al. (Online Ref. 47) showed that computed
tomography–guided annular sizing reduced paravalvular
AR compared with a TEE-guided approach in patients
Figure 6 Sensitivity Analysis Performed by Excluding One Stud
HR for all-cause mortality was statistically insignificant on removal of the papers b
Fraccaro et al. (16), with a shift of the overall HR to the left and crossing 1, therereceiving an Edwards SAPIEN valve (7.5% vs. 21.9%).Willson et al. (Online Ref. 42) and Schultz et al. (Online
Ref. 44) also showed the superiority of multidetector com-
puted tomography annular measurements. A high correla-
tion between multidetector computed tomography and
3-dimensional (3D) TEE measurements of annulus size
have been demonstrated in experienced hands. Therefore, it
is fair to conclude that 3D imaging for annulus sizing holds
the key to better sizing the valves and decreasing paraval-
vular leaks.
Aortic valve calcium score. Aortic root calcium is thought
to hinder uniform valve expansion and tight sealing. How-
ever, existing data on this topic are conflicting. In the
analysis of the German TAVI registry on 1,365 patients,
Staubach et al. (Online Ref. 57) found that the extent of
aortic valve calcification did not influence the severity of
post-TAVR AR, which is similar to that reported by Wood
et al. (Online Ref. 56). Other investigators found that an
Agatston score 3,000 predicted moderate or severe AR
after initial release of the CoreValve (Online Refs. 41,50,52)
and the need for post-dilation. Likewise, other quantitative
calcium scores also have been shown to correlate positively
with the occurrence of post-TAVR AR (Online Refs.
54,55). Despite the conflicting evidence, precise quantita-
tion of the extent and location of calcification in the aortic
root may allow the identification of patients with asymmet-
ric heavy calcification that may increase the risk of AR.
Implantation depth. Post-procedural AR is influenced
significantly by the implantation depth. Valve positioning
currently is based mainly on fluoroscopy and angiography
with or without echocardiographic guidance. Choosing the
correct fluoroscopic plane is critical. When misplaced high
or low, the skirt of the prosthetic valve does not provide an
adequate seal around the annulus, resulting in AR. The
unequal geometry of the CoreValve with a narrow and
tapered midsection further contributes to paravalvular leak
from an inadequate seal when misplaced. Takagi et al.
(Online Ref. 45) showed that low CoreValve implantation
increased the OR of moderate or severe AR, 3.67 (95% CI:
1.01 to 13.35). Sherif et al. (Online Ref. 58) and Jilaihawi et
Time for HRs of Mild AR on Overall Mortality
os et al. (14), Kodali et al. (10), Sinning et al. (15), and
icating no increased risk of mild AR. Abbreviations as in Figures 2 and 4.y at a
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cusp minimized the risk of moderate or severe AR for the
CoreValve. Improvements in imaging technology to provide
real-time 3D imaging, increasing experience and modifica-
tions in delivery systems, will likely improve the precision of
valve deployment.
Clinical implications and future perspective. Moderate
or severe AR post-TAVR is common but can be prevented
by accurate annulus measurements with 3D techniques and
adequate valve sizing. Accurate positioning of the valves
may reduce the risk of paravalvular AR. Post-TAVR AR is
difficult to quantitate with any single currently available
imaging technique and should be accurately quantified using
multimodality imaging with hemodynamic data. The next
generation of transcatheter aortic valves designed to mini-
mize paravalvular leak will have a major role to play in the
future of TAVR.
Study limitations. The studies pooled in the analysis were
bservational studies with post-TAVR AR not being a
rimary outcome of interest. The included studies used
ifferent methods and grading schemes for assessment of
R severity, thereby introducing limitations in quality and
ompleteness of data. There was significant heterogeneity
cross studies for all outcomes analyzed. Because of incom-
lete/unequal reporting of data, not all studies were pooled
or all outcomes, which could lead to publication bias.
election bias was introduced in the evaluation of the
rognostic value of mild AR by our method of contacting
uthors. Precise distinction between paravalvular and valvular
R was not made. AR varies with time; therefore, our
efinition of post-procedural AR may not be precise. Expan-
ion of the CoreValve over time was not taken into account, a
act that may have biased the results of post-procedural AR in
avor of the Edwards valve (however, at present there are no
ata to indicate that expansion of the CoreValve caused by
adial forces in the inflow portion reduces AR over time).
espite these limitations, the large sample size and robustness
f our findings clearly demonstrate the need for ongoing
ritical evaluation of this problem.
onclusions
oderate or severe AR is common after TAVR and an
dverse prognostic indicator of short- and long-term sur-
ival. Every effort should be made to predict and minimize
ost-procedural AR. Underestimation of paravalvular AR
ith currently used imaging modalities may be significant,
nd some patients with reported mild AR post-TAVR may
ave moderate or even severe AR. Sizing of the annulus is a key
tep to prevent post-procedural AR where sizing with 3D
maging is superior to 2-dimensional imaging techniques.
nnovations designed to improve sealing, improvement in the
ange of available device sizes, accurate annular sizing, and
recise positioning will help minimize AR after TAVR.Reprint requests and correspondence: Dr. Samir R. Kapadia,
Cardiac Catheterization Laboratory, Cleveland Clinic, 9500 Eu-
clid Avenue, J2-3, Cleveland, Ohio 44195. E-mail: kapadis@
ccf.org.
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